234 related articles for article (PubMed ID: 20410528)
1. Drug resistance, epigenetics, and tumor cell heterogeneity.
Hoey T
Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Bishop PC; Myers T; Robey R; Fry DW; Liu ET; Blagosklonny MV; Bates SE
Oncogene; 2002 Jan; 21(1):119-27. PubMed ID: 11791182
[TBL] [Abstract][Full Text] [Related]
3. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; CalabrĂ² L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
6. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.
Manna SK; Gangadharan C
Mol Immunol; 2009 Apr; 46(7):1340-50. PubMed ID: 19128834
[TBL] [Abstract][Full Text] [Related]
7. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
9. On or off target: mutations, models, and predictions.
Garraway LA; Hahn WC
Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
11. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
12. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
McDermott U; Settleman J
J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
[TBL] [Abstract][Full Text] [Related]
13. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Zhou CC; Deng XF
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
[No Abstract] [Full Text] [Related]
17. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
18. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
Bagrodia S; Smeal T; Abraham RT
Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
[TBL] [Abstract][Full Text] [Related]
20. Cancer cells acquire resistance to anticancer drugs: an update.
Lu HP; Chao CC
Biomed J; 2012; 35(6):464-72. PubMed ID: 23442359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]